Overview
NEO market data
Price History
NEO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.84 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.84 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.72 – $13.74 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.2K · P/B 1.82 · P/S 1.61.
Company news
Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $16Benzinga · Jul 24, 2026, 12:40 PM
8-K/A filing — NEOGENOMICS INC (NEO)SEC EDGAR · Jul 22, 2026, 11:00 AM
NeoGenomics Reveals Settlement Of Voluntary Disclosure To OIG-HHS; Co To Pay $9,813,260 Plus Interest At A Rate Of 4.250% Per Annum From January 16, 2026 To Resolve The MatterBenzinga · Jul 20, 2026, 9:30 PM
8-K filing — NEOGENOMICS INC (NEO)SEC EDGAR · Jul 20, 2026, 9:27 PM
NeoGenomics Launches PTEN IHC CDx, Immunohistochemistry Companion Diagnostic Test Approved By FDA For Patients With Prostate AdenocarcinomaBenzinga · Jul 9, 2026, 11:20 AM
NeoGenomics Commences A Private Offering Of $275M Aggregate Principal Amount Of Convertible Senior Notes Due 2032Benzinga · Jun 15, 2026, 9:55 PM
NeoGenomics To Showcase Eight Scientific Abstracts, Highlighting Advances In MRD, Precision Oncology, And Real-World Evidence Across Solid Tumors And Hematologic Malignancies, At 2026 ASCO Annual MeetingBenzinga · May 26, 2026, 11:15 AM